Physician profile

Ginger E Coleman

Surgery · Temple, TX

NPI 1639581622

$2,428.56

in general payments reported to CMS, 2019-2025

3 companies · $17.97 in 2025

The $17.97 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Education$1,500.00
Travel and Lodging$658.84
Food and Beverage$198.78

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $2,378.66 2021-2024
Avanos Medical $31.93 2019
Dendreon Pharmaceuticals LLC $17.97 2025 Provenge

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Ginger E Coleman

$2,428.56

in general payments reported 2019-2025

Years
2019-2025
Top company
Intuitive Surgical, INC.
Context
The $17.97 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).

https://glasscript.com/doctor/7232807/ginger-e-coleman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.